Infliximab neutralizes the biological activity of TNFα by binding with high affinity to the soluble and transmembrane forms of TNFα and inhibits binding of TNFα with its receptors.

Indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult and pediatric (6 years and older) patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy. It is also indicated for Ulcerative Colitis, Pediatric Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, and Plaque Psoriasis.

The recommended dosage of Infliximab is 5 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of adults with moderately to severely active CD.

An infusion reaction was defined in clinical trials as any adverse event occurring during an infusion or within 1 hour after an infusion.

Infliximab doses >5 mg/kg in moderate or severe heart failure. Previous severe hypersensitivity reaction to infliximab or any inactive ingredients of Infliximab or to any murine proteins.

Patients treated with Infliximab are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death.